Full Press Release Details
Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"),
a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight
disease, today announced that its management team is scheduled to participate in two upcoming virtual investor conferences in
Roth Virtual Conference
Panel Discussion: Therapeutics
Against SARS-CoV-2 - Viral Variants Will Not Fade Away
Panel Date: Monday, March 15, 2021
Panel Time: 12:00 PM Eastern Time
Interested parties may register for the panel here
31st Annual Healthcare Conference
Date: Tuesday, March 16, 2021
Presentation Time: 1:10 PM Eastern Time
Interested parties may register for the panel here
contact your representative at either Roth or Oppenheimer to schedule a virtual one-on-one meeting with INmune Bio during the
respective conference.
Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target
the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative
technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases.
DN-TNF is currently being developed for COVID-19 complications (Quellor ), cancer (INB03 ), Alzheimer's (XPro595),
and NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's
NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision
medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn
more, please visit www.inmunebio.com.
about Forward-Looking Statements
Clinical trials are in early
stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that
do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained
herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing
of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of
these risks and uncertainties. INB03 , Quellor , XPro1595, LIVNate , and INKmune are still in clinical
trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved
or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more
drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to
conduct research and development, clinical studies and future product commercialization; and, the Company's business, research,
product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified
and described in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's
Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form
8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance
that may arise after the date of this release.
LifeSci Advisors, LLC